Loading clinical trials...
Loading clinical trials...
A Phase 2, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of Motavizumab (MEDI-524), a Humanized Enhanced Potency Monoclonal Antibody Against Respiratory Syncytial Virus (RSV), and Palivizumab When Administered in the Same Season
Conditions
Interventions
Motavizumab, palivizumab
Palivizumab, motavizumab
+1 more
Locations
19
Australia
Department of Paediatrics and Child Health, The Canberra Hospital
Garran, Australian Capital Territory, Australia
Neonatalogy John Hunter Hospital
New Lambton Heights, New South Wales, Australia
Caboolture Clinical Research
Caboolture, Queensland, Australia
University of Queensland, Royal Children's Hospital
Herston, Queensland, Australia
Peninsula Clinical Research Centre
Kippa-Ring, Queensland, Australia
Women's and Children's Hospital
North Adelaide, South Australia, Australia
Start Date
April 1, 2006
Primary Completion Date
February 1, 2007
Completion Date
February 1, 2007
Last Updated
December 11, 2012
NCT07220109
NCT07092865
NCT07239583
NCT06534892
NCT04919109
NCT07235397
Lead Sponsor
MedImmune LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions